2003
DOI: 10.1128/aac.47.11.3407-3414.2003
|View full text |Cite
|
Sign up to set email alerts
|

Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces

Abstract: Staphylococci often form biofilms, sessile communities of microcolonies encased in an extracellular matrix that adhere to biomedical implants or damaged tissue. Infections associated with biofilms are difficult to treat, and it is estimated that sessile bacteria in biofilms are 1,000 to 1,500 times more resistant to antibiotics than their planktonic counterparts. This antibiotic resistance of biofilms often leads to the failure of conventional antibiotic therapy and necessitates the removal of infected devices… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
173
0
6

Year Published

2006
2006
2014
2014

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 267 publications
(182 citation statements)
references
References 42 publications
3
173
0
6
Order By: Relevance
“…This PIAse, named dispersin B, has first been found in Actinobacillus actinomycetemcomitans, and appears to have potential as an anti-biofilm drug (Kaplan et al 2003). Similarly, although not biofilm-specific, the peptidoglycan-degrading enzyme lysostaphin is being evaluated for therapeutic use against biofilm-forming staphylococci (Wu et al 2003).…”
Section: Interfering With Essential Staphylococcal Biofilm Factorsmentioning
confidence: 99%
“…This PIAse, named dispersin B, has first been found in Actinobacillus actinomycetemcomitans, and appears to have potential as an anti-biofilm drug (Kaplan et al 2003). Similarly, although not biofilm-specific, the peptidoglycan-degrading enzyme lysostaphin is being evaluated for therapeutic use against biofilm-forming staphylococci (Wu et al 2003).…”
Section: Interfering With Essential Staphylococcal Biofilm Factorsmentioning
confidence: 99%
“…In combination with lysostaphin, oxacillin or vancomycin, showed increased efficacy against MRSA (Kokai-Kun et al, 2007, Patron et al, 1999. Several workers demonstrated the effectiveness of lysostaphin in the treatment of biofilms formed by S. aureus and S. epidermidis and disruption of biofilms on glass and plastic surfaces (King et al, 1980, Walencka et al, 2005, Wu et al, 2003. Evaluation of PEGylation potential in improving lysostaphin pharmacokinetics showed substantial increase in serum drug half-life and reduced binding to anti-lysostaphin antibodies while maintaining the enzyme's lytic activity .…”
Section: Lysostaphin As a Therapeutic Agentmentioning
confidence: 99%
“…However, its activity against coagulase -negative staphylococci is essentially weaker due to a different amino acid composition of their cross -bridges (Kumar 2008 ). Aside from planktonic staphylococcal cells, lysostaphin can also specifi cally eliminate staphylococcal biofi lms (Wu et al 2003 ).…”
Section: Lysostaphinmentioning
confidence: 99%